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Background: The active site of O-GlcNAcase (OGA) is larger than needed to process O-GlcNAc from proteins.
Results: GlcNGc is assimilated to form UDP-GlcNGc and to generate O-GlcNGc, which can be removed by OGA.
Conclusion:OGA has a conserved active site that enables processing of O-GlcNGc.
Significance: Substrate tolerance of OGA occurs to process metabolic variants of O-GlcNAc.
TheO-GlcNAcmodification involves the attachment of single
-O-linked N-acetylglucosamine residues to serine and threo-
nine residues of nucleocytoplasmic proteins. Interestingly, pre-
vious biochemical and structural studies have shown that
O-GlcNAcase (OGA), the enzyme that removesO-GlcNAc from
proteins, has an active site pocket that tolerates various N-acyl
groups in addition to the N-acetyl group of GlcNAc. The
remarkable sequence and structural conservation of residues
comprising this pocket suggest functional importance. We
hypothesized this pocket enables processing of metabolic vari-
ants ofO-GlcNAc that could be formeddue to inaccuracywithin
the metabolic machinery of the hexosamine biosynthetic path-
way. In the accompanying paper (Bergfeld, A. K., Pearce, O. M.,
Diaz, S. L., Pham, T., and Varki, A. (2012) J. Biol. Chem. 287,
28865–28881),N-glycolylglucosamine (GlcNGc) was shown to be a
catabolite of NeuNGc. Here, we show that the hexosamine sal-
vage pathway can convert GlcNGc to UDP-GlcNGc, which is
then used to modify proteins with O-GlcNGc. The kinetics of
incorporation and removal of O-GlcNGc in cells occur in a
dynamic manner on a time frame similar to that of O-GlcNAc.
Enzymatic activity of O-GlcNAcase (OGA) toward a GlcNGc
glycoside reveals OGA can process glycolyl-containing sub-
strates fairly efficiently. A bacterial homolog (BtGH84) of OGA,
from a human gut symbiont, also processes O-GlcNGc sub-
strates, and the structure of this enzyme bound to a GlcNGc-
derived species reveals the molecular basis for tolerance and
binding of GlcNGc. Together, these results demonstrate that
analogs of GlcNAc, such as GlcNGc, are metabolically viable
species and that the conserved active site pocket of OGA likely
evolved to enable processing of mis-incorporated analogs of
O-GlcNAc and thereby prevent their accumulation. Such plas-
ticity in carbohydrate processing enzymes may be a general
feature arising from inaccuracy in hexosamine metabolic
pathways.
In nature, the biosynthesis of centrally important biomol-
ecules, such as DNA and protein, is prone tomis-incorporation
ofmonomeric units arising from a low level of inaccuracy in the
biosynthetic machinery (1, 2). In some cases, such mis-incor-
poration errors have been proposed to offer evolutionary ben-
efits (3, 4), while in other cases it can be detrimental. As a result
of the apparently unavoidable laxness in the accuracy of even
the most efficient enzymes, editing mechanisms are critical to
ensure that the accumulation of such errors in proteins and
nucleic acids is minimized (5–7). Carbohydrates, unlike DNA
and protein, are not synthesized using a chemically defined
template but instead their biosynthesis is governed by the tis-
sue-specific expression of the enzymes responsible for their
biosynthesis (the glycosyltransferase superfamily) as well as the
cellular localization of these enzymes and their substrates (8).
Glycosyltransferases have been found in many cases to be sur-
* This work was supported in part by National Institutes of Health Grant
R01GM32373 (to A. V.). This work was also supported by the Canadian Insti-
tutes for Health Research and the Natural Sciences and Engineering
Research Council of Canada (to D. J. V.).
□S This article contains supplemental Fig. S1, Scheme 1, and Table S1.
The atomic coordinates and structure factors (codes 4aiu and 4ais) have been
deposited in the Protein Data Bank, Research Collaboratory for Structural
Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).
1 Recipient of a senior scholarship from the Michael Smith Foundation for
Health Research and Natural Sciences and Engineering Research Council
of Canada.
2 Recipient of Ph.D. support from the Wild Fund of the University of York.
3 Recipient of support from the Australian Research Council.
4 Royal Society/Wolfson Research Merit Award recipient and supported by
the Biotechnology and Biological Sciences Research Council.
5 Canada Research Chair in Chemical Glycobiology, a scholar of the Michael
Smith Foundation for Health Research, and an E. W. R. Steacie Memorial
Fellow. To whom correspondence should be addressed: 8888 University
Drive, Burnaby, British Columbia V5A 1S6, Canada. Tel.: 604-291-3530; Fax:
778-782-3765; E-mail: dvocadlo@sfu.ca.
Final version published as: Bergfeld, A. K., Pearce, O. M. T., Diaz, S. L., Lawrence, R., Vocadlo, D. J., Choudhury, B., Esko, J. D., & Varki, A. (2012). 
Metabolism of Vertebrate Amino Sugars with N-Glycolyl Groups: INCORPORATION OF N-GLYCOLYLHEXOSAMINES INTO MAMMALIAN GLYCANS BY 
FEEDING N-GLYCOLYLGALACTOSAMINE *. Journal of Biological Chemistry, 287(34), 28898–28916. https://doi.org/10.1074/jbc.M112.363499
gosaccharides. The O-GlcNAc modification is found on pro-
teins with a wide range of functions and appears to be essential
for life at the single cell level (14). GlcNAc is installed by an
enzyme termed O-GlcNAc transferase (OGT),6 which uses
UDP-GlcNAc as a substrate (Fig. 1A) (15, 16). UDP-GlcNAc is
itself a product of the hexosamine biosynthetic pathway
(HBSP) (Fig. 1A). This pathway involves four enzymes that con-
vert fructose 6-phosphate, an intermediate in glycolysis, to
UDP-GlcNAc. Intermediates in the pathway such as glucosa-
mine (GlcN) and GlcNAc can also be incorporated into the
pathway by a salvage pathway (the hexosamine salvage pathway
(HSP)) involving enzymes that phosphorylate these species to
formGlcN-6-P andGlcNAc-6-P, respectively. Another enzyme
termedO-GlcNAcase (OGA) catalyzes hydrolysis of the glyco-
sidic linkage between GlcNAc and the protein to return pro-
6 The abbreviations used are: OGT, O-GlcNAc transferase; HBSP, hexosamine bio-
synthetic pathway; GlcNGc, N-glycolylglucosamine; OGA, O-GlcNAcase; HSP,
hexosamine salvage pathway; NeuNGc, N-glycolylneuramic acid; ManNGc,
N-glycolylmannosamine; ddH2O, double distilled H2O; Hex, hexosaminidase;
rcf, relative centrifugal force; pNP-GlcNGc, 4-nitrophenyl 2-deoxy-2-hydroxy-
acetamido--D-glucopyranoside; GalNGc, N-glycolylgalactosamine.
FIGURE 1. The Hexosamine biosynthetic pathway leads to the formation of UDP-GlcNAc, which is the donor substrate used by OGT to form the
O-GlcNAc modification, which is in turn processed within the conserved active site pocket found in human OGA and homologs. A, O-GlcNAc consists
of serine and threonine residues modified with a single -O-linked N-acetylglucosamine (GlcNAc) residue. Installation of O-GlcNAc is catalyzed by OGT, which
uses UDP-GlcNAc as a substrate. Removal of O-GlcNAc from modified proteins is catalyzed by OGA. UDP-GlcNAc is made from the hexosamine biosynthetic
pathway (box). GlcNAc can be salvaged by phosphorylation to generate the HBSP intermediate GlcNAc-6-P. UDP-GlcNAc is also used for the biosynthesis of
CMP-Neu5Ac and UDP-GalNAc. B and C, a conserved active site pocket is present around the 2-acetamido substituent in all GH84 family members. B, structure
of BtGH84 with NAG-thiazoline bound in its active site (Protein Data Bank code 2CHN). Highlighted are residues that line the active site including the pocket
formed beneath the 2-methyl group of NAG-thiazoline. C, sequence alignment of several GH84 family members. Residues in boldface are those that line the
active site pocket. Note that Asp-242, Phe-240, Thr-310, and Val-314 are not noted in B because they are either out of plane (into the page) or obscured.
prisingly tolerant to variation in the structure of their preferred 
substrates. Indeed, some organisms exploit this substrate 
promiscuity by diversifying the repertoire of available sub-
strates (9). These “errors,” which arise from the loose substrate 
specificity of the enzyme, can give rise to further diversification 
of an already heterogeneous population of glycoforms (10). 
Such variations may offer evolutionary advantages (11) or, 
alternatively, remain as an evolutionary relic (12). It is impor-
tant to point out, however, that cells must be able to degrade the 
full complement of glycoconjugates to recycle individual com-
ponents and avoid the deleterious accumulation of these spe-
cies. This requirement is underscored by the existence of dis-
ease states, such as the set of lysosomal storage diseases, in 
which various glycoconjugates accumulate to toxic levels due to 
the inability of cells to catabolize certain glycoconjugates (13).
Heterogeneity is well established in forms of glycosylation 
that exists on the extracellular side of the plasma membrane. 
However, the modification of proteins within the nucleus and 
cytoplasm with a single -O-linked N-acetylglucosamine 
(O-GlcNAc) has been, to date, described as a having an invari-
able structure and linkage and lacking elongation to form oli-
strate the molecular basis for the ability of OGA to process a
glycolyl substrate through the crystal structure of a trapped
GlcNGc reaction intermediate. We propose that OGA has
evolved this ability to compensate for metabolic promiscuity in
the HSP and HBSP, as well as in OGT, and that without such a
proofreading function, O-GlcNGc could accumulate on pro-
teins in an irreversible manner.
EXPERIMENTAL PROCEDURES
General
CTD110.6 was obtained from Covance, and the RL2 and
HGAC85 antibodies were obtained fromAbcam. Secondary anti-
bodies were obtained from Santa Cruz Biotechnology. Human
placental hexosaminidase B (HexB) was obtained from Sigma.
Cell Culture
EMEG/ and EMEG/ cells were cultured in standard
DMEM (Invitrogen) containing 5% fetal bovine serum
(HyClone). Cells were passaged every 2–3 days. The growth
rate of EMEG cells was determined as follows: 5000 cells were
plated onto 12-well plates and counted 5 days later using a
hemocytometer. During these 5 days of growth, themedia were
replaced after 2 and one-half days to ensure that nutrients
and/or supplements were not depleted. All counting was car-
ried out in a minimum of three replicates. For experiments
involving HPLC analysis of sugars digested from proteins by an
N-acetylglucosaminidase from Bacteroides thetaiotaomicron
(BtGH84), EMEG/ cells (5  106) were plated onto 175-cm
flasks and treated with 5 mM GlcNAc, GlcNGc, or PBS as a
control. The cells were grown for 48 h, at which time the cells
reached confluence. The cells were washed with 5 ml of PBS,
3ml of trypsin solutionwas added, and the cells were incubated
for 3 min at 37 °C to detach the cells from the plate. The buffer
and cells were then transferred to a 15-ml conical tube and
pelleted by centrifugation (250 rcf, 8 min), and the supernatant
was carefully removed. The cell pellet was stored at 80 °C
until further processing.
Immunoblotting
Procedures for Western blotting are the same as those
described previously (31). The dilutions of the three anti-
O-GlcNAc antibodies used were 1:4000, 1:500, and 1:1000,
respectively, for CTD110.6, RL2, and HGAC85. To block bind-
ing of the CTD110.6 antibody using either GlcNAc or GlcNGc,
the antibody was first made up to the appropriate dilution in
PBS-T containing 1% BSA. The appropriate amount of sugar
was then incubated with this antibody solution for 10 min at
room temperature, and this solution was used directly to probe
the membranes.
Cloning
The cDNA encoding human GalE was obtained from Ori-
gene and amplified by PCR using the following two primers:
5-AGCAGCCATATGATGGCAGAGAAGGTGCTGG-3 (NdeI
cut site shown in boldface) and 5-AGCAGCCTCGAGTCAG-
GCTTGCGTGCCAAAGCC-3 (XhoI cut site shown in bold-
face). The PCR product was digested with NdeI and XhoI and
teins to their unmodified state. The actions of OGA give the 
O-GlcNAc modification a dynamic nature since it has been 
demonstrated that the lifetime of O-GlcNAc on a protein is less 
than the polypeptide backbone of the protein to which it is 
attached (17).
Through a series of biochemical and structural studies (18 –
23), it has been firmly established that OGA harbors an unusu-
ally large active site pocket located directly below the 2-acet-
amido group of the substrate (Fig. 1B). The residues that line 
this pocket are conserved among eukaryotic homologs of 
human OGA and even among homologs from pathogenic and 
symbiotic bacteria (Fig. 1C). The near complete conservation of 
these residues suggests functional importance. Yet, within 
mammals, no derivative of GlcNAc bearing a larger substituent 
than the 2-acetamido group has been shown to occur naturally. 
Interestingly, however, the HBSP as well as OGT have been 
shown to have some plasticity in substrate recognition because 
they can readily use a substrate with an azido substituent 
appended off the 2-acetamido group of GlcNAc (24).
We were stimulated to look for a derivative of GlcNAc and 
found a number of older studies pointing toward the possible 
existence of one such species. One intriguing study has shown 
that glucosamine 6-phosphate acetyltransferase (GNAT) can 
accept glycolyl-CoA as a substrate to form N-glycolylglucos-
amine 6-phosphate (GlcNGc) (Fig. 1a). Given that glycolyl-
CoA is itself naturally produced in cells from -hydroxylated 
fatty acids (25) makes the production of a GlcNGc species plau-
sible. However, as shown in an accompanying paper (26), met-
abolic feeding of glycolic acid does not lead to the formation of 
GlcNGc suggesting that this route is improbable. More com-
pelling is another possible route. Catabolism of N-glycolyl-
neuramic acid (Neu5Gc) proceeds to generate N-glycolylman-
nosamine (ManNGc) via an enzyme termed N-acylneura-
minate pyruvate lyase (27). In the preceding accompanying 
paper (26), it is clearly shown that ManNGc can be converted to 
GlcNGc by GlcNAc 2-epimerase and to GlcNGc 6-phosphate. 
The demonstration that GlcNGc and GlcNGc 6-phosphate are 
true catabolic intermediates within cells is significant. In vitro 
studies using sheep tissue extracts have shown that GlcNGc can 
be converted to GlcNGc-6-P and then to GlcNGc-1-P (28), and 
purified GlcNAc-6-P phosphomutase from pig could convert 
GlcNGc-6-P to GlcNGc-1-P with only a 3-fold decrease in cat-
alytic efficiency compared with GlcNAc-6-P (29). Given that 
OGT can modify protein with 2-azidoacetamido-2-deoxy-D-
glucopyranose (24), which is similar in size to GlcNGc, it 
seemed probable that if UDP-GlcNGc could be formed in cells 
it could be transferred to proteins as O-GlcNGc.
With these thoughts in mind, studies were initiated to test 
two hypotheses. The first hypothesis is that GlcNGc can be 
salvaged through the HSP and HBSP to generate UDP-GlcNGc 
within cells. The second is that GlcNGc can enter into the 
O-GlcNAc cycle to form O-GlcNGc-modified proteins through 
the action of OGT and then be removed by the action of OGA. 
Here, we report multiple lines of evidence supporting both of 
these hypotheses. The results offer a clear rationale for the pres-
ence of the highly conserved active site pocket found in OGA 
and other GH84 enzymes (for a review of the classification sys-
tem of glycoside hydrolases see Ref. 30). We further demon-
ligated into pET28a to produce a construct with an N-terminal
His6 tag. The clone for SpHex, in pET15 encoding an N-termi-
nal His6 tag, was obtained as a gift from Dr. Brian Mark (Uni-
versity of Manitoba). The gene encoding human Agx1, in the
pTrcHisB expression vector encoding an N-terminal His6 tag,
was obtained as gift from Véronique Piller (Université
d’Orléans). Cloning of human OGA and BtGH84 into pET28a
to encode fusion proteins with an N-terminal His6 tag has been
described previously (18, 32).
Protein Expression—All vectors were transformed into
TunerTM(DE3) cells (Stratagene) and selected with either 50
g/ml kanamycin or 100 g/ml ampicillin with the exception
that SpHex was selected with only 25 g/ml ampicillin. Cells
containing the plasmids were grown until an A600 of 1.0 was
reach, after which time protein expression was induced by addi-
tion of 0.5 mM isopropyl 1-thio--D-galactopyranoside for 3–4 h
at 25 °C. Bacteria were pelleted, lysed, and purified by nickel che-
late affinity chromatography using a previously reported proce-
dure (32).
(Fluka) and was filtered through a 0.22-m filter (Millipore)
prior to use. Before samples were introduced, the capillary was
conditioned by washing sequentially with 1 N NaOH (2 min,
20 p.s.i.), ddH2O (3 min, 20 p.s.i.), and running buffer (5 min,
40 p.s.i.). To ensure reproducible migration times, the running
buffer was replaced after every second run. After injecting a
short (15 nanoliters)H2Oplug, sampleswere electrostatically
introduced and pre-concentrated at the anode by applying a
potential of10 kV for 10 s according to a field-amplified sam-
ple injection technique described previously (37). Electropho-
resis was carried out at a constant voltage of 30 kV (which pro-
duced a current of about 90 A), and the capillary was
thermostated at 22 °C. Electrophoretograms were derived by
measuring the absorbance at 254 (10) nm at a rate of 4 Hz.
Peaks were integrated using 32 Karat 5.0 software (Beckman-
Coulter), and all data were normalized to the GDP-Glc internal
standard. All NDP-sugar standards, as well as GlcNAc-1-P,
were obtained from Sigma, except for UDP-GlcNGc and UDP-
GalNGc, which were made as part of this work.
Large Scale Digestion of Lysates with BtGH84
Cell pellets were thawed on ice and resuspended in 1 ml of
buffer consisting of 10 mM sodium phosphate and 10 mM
sodium chloride, pH 6.5. Solutions weremade up very carefully
with the highest quality salts and water to avoid small amounts
of contaminant that would be concentrated over the following
steps. Low amounts of salts and buffer were used to minimize
the salt content. The cells were lysed by passing the solution up
and down through a 27-gauge needle three times. This suspen-
sion was sonicated (two times for 20 s at 15% duty) followed by
centrifugation (17,900 rcf, 20 min) to clarify the supernatant.
The supernatant was made up to 2.5 ml with the same low salt
buffer and desalted using a PD-10 column equilibrated in same
low salt buffer as the eluent. One round of desalting did not
efficiently desalt the samples; therefore, the 3.5 ml of elution
obtained after the first column was further diluted to 5 ml and
split into two 2.5-ml aliquots, which were desalted a second
time. These eluted proteins were combined (7 ml in total), and
fucose andmaltosewere added as internal standards (1M final
concentration) to enable a percentage recovery to be calculated.
These solutions were treated at 37 °C for 1 h with 200 l of 1
mg/ml BtGH84 (that had been dialyzed in the same low salt
buffer) or 200l of buffer as a control. One set of lysateswas not
incubated at 37 °C but insteadwas kept on ice to control for any
molecules that were not removed by desalting and/or released
by endogenous glycosidases during the 1-h 37 °C incubation
step. Following glycosidase digestion, the samples were con-
centrated down to 1 ml on a speed vac (Thermo) heated to
55 °C, and the protein was then precipitated from the reactions
by the addition of 7 ml of 95% cold ethanol, and the resulting
mixtureswere incubated at20 °C for 30min. The precipitated
protein was pelleted by centrifugation (4000 rpm, 15 min). The
supernatant was gently decanted and then lyophilized (over-
night). The precipitate was resuspended in 2ml of methanol by
extensive vortexing. Any precipitate that did not dissolve was
removed by centrifugation (17,900 rcf, 10 min), and the super-
natant was evaporated using a speed vac heated to 55 °C. The
residue was taken back up in 150 l of ddH2O. These solutions
Nucleotide Diphosphate Extraction
Nucleotide diphosphate sugars were extracted from cells 
according to established procedures (33, 34). EMEG/ cells 
were plated onto 10-cm plates and grown to 50% confluence 
and then treated with either 5 mM GlcNAc or 5 mM GlcNGc or 
PBS as a control. Each growth condition was carried out in 
triplicate. After 48 h, a time when the cells have reached con-
fluence, the plates of cells were washed once with PBS before 
the addition of 1 ml of PBS containing 10 mM EDTA. Cells were 
incubated at 37 °C for 4 min, scraped from the plates using a 
rubber policeman, transferred into 1.5-ml centrifuge tubes, and 
placed on ice prior to pelleting by centrifugation (100 rcf, 10 
min, 4 °C). Cell pellets were immediately lysed by adding 750 l 
of pre-chilled (20 °C) 75% ethanol and sonicating these sam-
ples using a W-375 ultrasonic processor (Heat Systems Ultra-
sonics, Inc.) using two blasts of 30 s each. Insoluble material was 
removed from the lysates by centrifugation (21,000 rcf, 15 min, 
4 °C), and the supernatants, which contained the sugar nucleo-
tides, were snap-frozen in liquid nitrogen and then lyophilized. 
To this crude extract was added GDP-Glc (200 pmol) as an 
internal standard, dissolved in 0.5 ml of ddH2O, and extracted 
using Envi-Carb graphite solid-phase extraction cartridges (200 
mg) (Supelco) exactly as described previously (35). Sugar nucle-
otides were eluted three times using 1 ml of 25% CH3CN in 50 
mM triethylammonium acetate, pH 7.0, passed through a 
0.22-m filter (Millipore), lyophilized, and stored in dry form at 
20 °C until analysis by capillary electrophoresis.
Capillary Electrophoresis
Lyophilized sugar nucleotides were dissolved in 200 l of  
ddH2O, and an aliquot was diluted 1:4 prior to characterization 
by capillary electrophoresis by adapting a previously reported 
method (36). Capillary electrophoresis was performed using a 
ProteomeLab PA800 (Beckman-Coulter) equipped with fused 
silica capillaries of 50 m internal diameter  44 cm length (to 
the detector). The running buffer, prepared from components 
of the highest available purity, was 40 mM Na2B4O7 (Sigma), pH 
9.5, containing 1.0% (w/v) polyethylene glycol (Mr 20,000)
a total of 100 l with various concentrations of substrate and
100 nM enzyme in 96-well plates. Reactions were initiated by
the addition of enzyme and monitored continuously at either
400 nM for OGA-catalyzed reactions or 340 nM for HexB-cata-
lyzed reactions on a 96-well plate reader. Initial rates of reaction
were obtained between the 2nd and 5th min of the reaction.
Rates were converted into absolute amount of product released
by comparing the absorbance values to a standard curve ofp-ni-





pyranose 2—Triethylamine (2.2 ml, 16 mmol) was added to a
solution of the hydrochloride salt of 2-amino-2-deoxy-1,3,4,6-
tetra-O-acetyl--D-glucopyranose 1 (39) (2.0 g, 5.2 mmol) in
CH2Cl2 (20 ml), at which time the starting material dissolved.
The reaction mixture was cooled to 0 °C, and acetoxyacetyl
chloride (0.7 ml, 6.5 mmol) was added. The resultant mixture
was stirred for 2 h at room temperature. When the reaction
mixture was judged complete by TLC analysis, the mixture was
diluted with EtOAc. The resulting organic phase was washed
successively with water, 1 MNaOH, and saturated sodium chlo-
ride. The organic phase was dried over MgSO4, filtered, and
concentrated to yield a white crystalline solid. Thematerial was
recrystallized using a mixture of ethyl acetate and hexanes to
yield the desired compound 2 as a white solid (2.0 g, 86%). For
1H NMR (600 MHz, CDCl3),   6.25 (1H, d, JNH-H2  9.2 Hz,
NH), 5.71 (1H, dd, JH1-H2  8.8 Hz, H-1), 5.19–5.11 (2H, m,
H-3/4), 4.53 (1H,A part of ABq, JH-H  15.4Hz, CH2), 4.40 (1H,
A part of ABq, CH2), 4.32 (1H, ddd, JH2-H3  9.1 Hz, H-2), 4.25
(1H, dd, JH5-H6  4.3 Hz, JH6-H6  12.3 Hz, H-6), 4.12 (1H, dd,
JH5-H6  2.2 Hz, H-6), 3.81 (1H, ddd, JH4-H5  9.2 Hz, H-5),
2.15 (3H, s, OAc), 2.10 (3H, s, OAc), 2.08 (3H, s, OAc), 2.02 (3H,
s, OAc), and 2.01 (3H, s, OAc). For 13C NMR (150 MHz,
CDCl3),   171.3, 170.6, 169.7, 169.6, 169.2, 167.5 (C  O),
92.4 (C-1), 73.0, 72.1, 67.6 (C-3, C-4, C-5), 62.6, 61.6 (C-6, CH2),
52.7 (C-2), 20.8, 20.7, 20.5 (OAc). For mass spectrometry, FAB
calculated for C18H26NO12 was 448.1455, and found was
448.1445. The melting point  168–169 °C. For C18H25NO12,
that calculated was C 48.32, H 5.63 and found was C 48.48, H
5.59.
2-Deoxy-2-hydroxyacetamido-D-glucopyranose (GlcNGc)—
Following a published synthetic strategy (40), a solution
of 1,3,4,6-tetra-O-acetyl-2-acetyloxyacetamido-2-deoxy--D-
glucopyranose 2 (1.5 g, 3.35 mmol) in MeOH (50 ml) was
treated with 0.5 M NaOMe (5 ml). The solution was stirred
overnight at room temperature. Amberlite resin (H form) was
added to neutralize the reaction and was filtered. The filtrate
was concentrated under reduced pressure to afford the desired
product as a white solid (711 mg, 90%) and m.p.  179.0–
180 °C. Spectral properties of the desired product (GlcNGc)
matched those described previously (40).
4-Nitrophenyl 2-deoxy-2-hydroxyacetamido--D-glucopy-
ranoside7—Asolution of 1,3,4,6-tetra-O-acetyl-2-acetyloxyac-
etamido-2-deoxy-D-glucopyranose 2 (250 mg, 0.56 mmol) and
4-nitrophenol (117 mg, 0.84 mmol) in anhydrous CH2Cl2 (10
were vortexed and then centrifuged (17,900 rcf, 5 min) to 
remove any insoluble debris, and the supernatant was collected 
for HPLC analysis of GlcNAc or GlcNGc content.
HPLC Analysis of Sugars Liberated by BtGH84 Digestion
Carbohydrates were separated by HPLC anion exchange chro-
matography using an ICS 3000 HPLC equipped with an ASI 100 
automated sample injector (Dionex) and detected using an elec-
trochemical detector (ED50, Dionex) using a gold working elec-
trode and an Ag/AgCl reference electrode. To detect GlcNAc, a 
CarboPac PA20 column was used, and isocratic elution was car-
ried out using 20 mM NaOH. Preliminary experiments designed to 
guide optimization of the assay showed that a GlcNGc standard 
was retained by the PA20 column and eluted very late in the chro-
matogram. The long retention time of GlcNGc reflects strong 
interaction with the solid phase of the column (immobilized qua-
ternary ammonium ion), and this interaction is much stronger 
than GlcNAc because the highly basic mobile phase likely results 
in partial deprotonation of the acidic group present on the glycolyl 
moiety. Therefore, for better detection of GlcNGc, a CarboPak 
PA100 column was used, and isocratic elution was carried out 
using 100 mM NaOH. In each case, 20 l of sample was injected; 
this was followed by 20 min of isocratic elution, followed by a 
5-min wash with 500 mM NaOH to clean the column between the 
samples. After washing, the column was equilibrated for a mini-
mum of 15 min in the same concentration of NaOH used to run 
the isocratic elution. A constant flow rate of 0.4 ml/min was used 
with the PA20 column, whereas a flow rate of 0.5 ml/min was used 
with the PA100 column, as per the manufacturer’s instructions. To 
assess the percent recovery and absolute amount of GlcNAc and 
GlcNGc present in the samples, standard curves of fucose, malt-
ose, GlcNAc, and GlcNGc were constructed for concentrations 
ranging from 0.5 to 50 M. GlcNAc (Bioshop), ManNAc (Jülich), 
maltose (Sigma), and fucose (Carbosynth) were obtained com-
mercially and carefully prepared in ddH2O to construct the stan-
dard curves.
Comparative Digests of Cell Lysates with SpHex and BtGH84
SpHex and BtGH84 were prepared as 1 mg/ml stocks in a 
buffer consisting of 50 mM sodium phosphate and 100 mM 
sodium chloride at pH 6.5. Cell lysates from EMEG/ cells 
cultured for 48 h with either GlcNAc or GlcGc were treated 
with either SpHex or BtGH84 at a final concentration of 0.1 
mg/ml and incubated at 37 °C. After various times, an aliquot of 
the reaction was removed and quenched by addition of SDS-
PAGE loading buffer and heated at 95 °C for 5 min. Samples 
were analyzed by Western blot using the CTD110.6 
anti-O-GlcNAc antibody as described above. Densitometric 
analysis was performed using ImageQuant software.
Enzyme Kinetics
The rates of OGA- and HexB-catalyzed hydrolysis of 
pNP-GlcNAc and pNP-GlcNGc (7) were measured using a 
continuous UV/visible assay as described previously (38). 
Briefly, 10 mM stocks of the two substrates were made up in 
either PBS or low pH citrate buffer (50 mM sodium citrate, 100 
mM sodium chloride, pH 4.5) for monitoring the OGA- and 
HexB-catalyzed reactions, respectively. Reactions consisted of
10 °C. Diphenyl chlorophosphate (0.9 ml, 4.3 mmol) was
added dropwise and the solution stirred (4 h), gradually warm-
ing to 10 °C. The solution was then diluted with CH2Cl2 (30ml)
and washed sequentially with cold water, 0.5 M HCl, and satu-
rated sodium bicarbonate solution, then dried (MgSO4), and
concentrated. Flash chromatography (EtOAc/hexanes, 1:3) of
the residue gave the -phosphate 5 as a colorless oil (730 mg,
83%). For 1H NMR (500 MHz, CDCl3),   7.38–7.32 (4H, m,
Ar), 7.24–7.18 (6H, m, Ar), 6.40 (1H, d, JNH-H2  8.4 Hz, NH),
6.04 (1H, dd, JH1-H2  3.2Hz, JH1-P  6.0Hz,H-1), 5.29 (1H, dd,
JH3-H4  9.7 Hz, JH4-H5  9.7 Hz, H-4), 5.22 (1H, dd, JH2-H3 
9.7Hz,H-3), 4.50 (1H,Apart ofABq, JH-H 15.5Hz,CH2), 4.39
(1H, m, H-2), 4.18–4.14 (2H, m, CH2, H-6), 4.06 (1H, ddd,
JH5-H6  2.0 Hz, JH5-H6  6.0 Hz, H-5), 3.89 (1H, dd, JH6-H6 
12.6 Hz, H-6), 2.06 (3H, s, OAc), 2.04 (3H, s, OAc), 2.03 (3H, s,
OAc), and 1.99 (3H, s, OAc). For 13C NMR (125 MHz, CDCl3),
  171.7, 170.5, 169.5, 168.9, 167.6 (C  O), 150.1, 129.9,
125.8, 119.8 (Ar), 96.6 (JC1-P  6.7 Hz, C-1), 70.1, 69.5, 66.7
(C-3, C-4, C-5), 62.3, 61.0 (C-6, CH2), 52.3 (JC2-P  8.0Hz, C-2),
20.5, 20.4, and 20.3 (OAc). For mass spectrometry, FAB calcu-
lated for C28H33NO14P was 638.1624 and found was 638.1639.
For C28H32NO14P, that calculated was C 52.75, H 5.06 and
found was C 52.68, H 5.13.
Bis(triethylammonium) 2-Hydroxyacetamido-2-deoxy--D-
glucopyranosyl Phosphate 6—PtO2 (40mg)was added to a solu-
tion of the -phosphate 5 (110 mg) in THF (5 ml), and the
mixture was stirred under an atmosphere of hydrogen gas (RT,
48 h).When the reaction was judged complete by TLC analysis,
the mixture was filtered through Celite and concentrated in
vacuo. The crude material was then resuspended in MeOH/
H2O/triethylamine (5:2:1, 5 ml) and stirred for 16 h at 4 °C and
then concentrated in vacuo to yield the phosphate 6 as a color-
less oil with no further purification required (85 mg, 98%). For
1H NMR (500 MHz, D2O),   5.39 (1H, dd, JH1-H2  3.3 Hz,
SCHEME 1. (i) AcOCH2C(O)Cl, Et3N, CH2Cl2; (ii) NaOMe, MeOH; (iii) BnNH2, THF; (iv) (PhO)2P(O)Cl, DMAP, CH2Cl2; (v) a; PtO2, THF; b, MeOH:H2O:Et3N (5:2:1);
(vi) 4-nitrophenol, BF3OEt2, CH2Cl2.
ml) was cooled to 0 °C in an ice bath. The solution was treated 
with boron trifluoride etherate (177 l, 1.4 mmol) and stirred at 
room temperature for 3 h. The reaction mixture was then 
washed successively with saturated NaHCO3 (20 ml), water (20 
ml), and brine (20 ml). The organic fraction was dried (Na2SO4) 
and concentrated under reduced pressure to give a syrup. This 
material was purified via flash chromatography (EtOAc/
hexanes, 1:1, v/v) to afford the intermediate 3 as an off-white 
solid. Deacetylation of 3 under Zemplén conditions afforded 
the desired compound 7 as a light-yellow solid (92 mg, 46% over 
two steps). For 1H NMR (600 MHz, D2O),   8.19 – 8.18 (m, 
2H, Ar-H), 7.15–7.11 (m, 2H, Ar-H), 5.33 (dd, J  8.4, 1.2, 1H, 
H-1), 4.10 –3.98 (m, 3H), 3.91–3.89 (m, 1H), 3.78 –3.70 (m, 2H), 
3.68 –3.61 (m, 1H), 3.54 (t, J  13.9, 1H), and 1.21 (bs, 1H, NH). 
For 13C NMR (151 MHz, D2O),   175.4 (C  O), 161.2, 142.2, 
125.6, 116.0 (Ar), 97.9 (C-1), 75.8 (C-5), 72.7 (C-3), 69.1 (C-4), 
60.4 (CH2O2), 59.9 (C-6), and 54.5 (C-2). The melting point  
188.5–189 °C. For C14H18N2O8, that calculated was C 49.12, H 




pyranose 4—To acetate 2 (1.0 g, 2.2 mmol) dissolved in THF 
(10 ml) was added benzylamine (0.4 ml, 3.5 mmol), and the 
mixture was kept (2 h). The mixture was then diluted with 
CH2Cl2 (30 ml) and washed sequentially with cold water, 0.5 M 
HCl, and saturated sodium bicarbonate solution, then dried 
(MgSO4), and concentrated affording a colorless oil (800 mg). 
This material, presumably the hemiacetal 4, was used in the 
next step without any further purification.
Diphenyl (3,4,6-Tri-O-acetyl-2-acetyloxyacetamido-2-de-
oxy--D-glucopyranosyl) Phosphate 5—A solution of the hemi-
acetal 4 (0.56 g, 1.4 mmol) and 4-dimethylaminopyridine 
(DMAP, 1.00 g, 8.2 mmol) in CH2Cl2 (30 ml) was cooled to
BtGH84-glycolic acid structure, above. Details of data and
final structure quality are shown in supplemental Table 1.
Coordinates have been deposited with the Protein Data Bank
under the codes 4aiu and 4ais.
RESULTS AND DISCUSSION
To begin our search for a viable metabolically-derived
GlcNAc analog, we felt that a cell line in which the biosynthesis
of UDP-GlcNAc is compromised would be useful. Because
UDP-GlcNAc is generally abundant in cells, lower levels of
UDP-GlcNAc would facilitate the observation of an analog of
GlcNAc and enhance the effects of feeding exogenous GlcNAc
analogs that would compete with GlcNAc derived through
the HBSP. It is known, however, that the biosynthesis of
UDP-GlcNAc is necessary for life; deletion of the gene encod-
ing glucosamine-6-phosphate acetyltransferase (EMEG32)
results in embryonic lethality in mice (47). Despite the fatal
consequence of deleting the EMEG32 gene at the organismal
level, mouse embryonic fibroblasts from EMEG32-deficient
embryos have been generated and readily propagated (47).
Although heterozygous (EMEG32/) cells have normal
growth rates and show levels of UDP-GlcNAc comparable with
those of WT cells, the growth rate of EMEG32/ cells is dra-
matically impaired, and their cellular UDP-GlcNAc levels are
1/50th the concentration of those found in EMEG32/ and
WT cells. It is likely that EMEG32/ cells derive this
UDP-GlcNAc from scavenging free GlcNAc and degrading
GlcNAc-containing glycans present in the serum used during
cell culture. Consistent with this view, we find that the growth
rate of EMEG/ cells is affected by serum concentration to a
much larger extent than are EMEG/ cells. Boehmelt et al.
(47) demonstrated that the slow growth rate and cellular levels
of UDP-GlcNAc of EMEG32/ cells could both be rescued by
addition of GlcNAc to the media. Thus, we felt that
EMEG32/ mouse embryonic fibroblasts would be an excel-
lent tool for investigating the effects of exogenously added
GlcNAc, or analogs thereof, on cells as well as evaluating the
tolerance of the HBSP to such compounds.
Rescue of the Growth Rate of EMEG/ Cells by GlcNGc and
ManNGc—Because OGA shows a highly conserved active site
pocket that most likely accommodates structural variants of
O-GlcNAc, we thought it would be interesting to see if cells
treated with metabolically viable analogs of GlcNAc could
incorporate these in place of O-GlcNAc. Earlier suggestions
regarding the existence of GlcNGc (25), and an accompanying
paper (26), which provides compelling evidence that both
GlcNGc and GlcNGc-6-phosphate are catabolic intermediates
derived from Neu5Gc, provide a clear rationale to evaluate
whether GlcNGc could be incorporated as O-GlcNGc. Using
EMEG32
/ cells, we observe that the growth rate of these cells
approached that of heterozygous cells when 10 mM GlcNAc
was added to the culture media (Fig. 2A). Heterozygous cells
showed no enhancement in growth rate when GlcNAc was
added to the culture media (Fig. 2B); results that are consistent
with previous studies using this cell line (47). In parallel, we
treated cells with varying concentrations of GlcNGc. In
EMEG32/ cells, GlcNGc rescued the growth rate in a dose-
dependent manner up to a concentration of 10 mM, such that
JH1-P  7.6 Hz, H-1), 4.15 (1H, A part of ABq, JH-H  16.5 Hz, 
CH2), 4.11 (1H, A part of ABq, CH2), 3.99 (1H, ddd, JH2-P  2.1 
Hz, JH2-H3  10.5 Hz, H-2), 3.94 (1H, ddd, JH5-H6  2.2 Hz, 
JH5-H6  5.1 Hz, JH4-H5  10.1 Hz, H-5), 3.89 –3.84 (2H, m, H-3, 
H-6),3.78(1H,dd, JH6-H6 12.4Hz,H-6),3.51(1H,dd, JH3-H4 9.2 
Hz, H-4), 3.20 (12H, q, JCH2-CH3  7.4 Hz, CH2CH3), and 1.28 
(18H, t, CH2CH3). For 13C NMR (125 MHz, D2O),   176.3 
(C  O), 93.1 (JC1-P  5.5 Hz, C-1), 73.3, 71.9, 70.8 (C-3, C-4, 
C-5), 62.0, 61.6 (C-6, CH2), 54.6 (JC2-P  7.7 Hz, C-2), 47.6 
(CH2CH3), and 9.2 (CH2CH3). For mass spectrometry, FAB cal-




Following a published synthetic strategy (41), a solution of 
mannosamine hydrochloride 8 (1.46 g, 6.77 mmol) and 
NaHCO3 (3.5 g, 42 mmol) in H2O (60 ml) was cooled in an 
ice-bath and treated with acetoxyacetyl chloride (3.9 ml, 36 
mmol). After stirring for 1 h, the solution was neutralized with 
aqueous HCl. The reaction mixture was concentrated under 
reduced pressure, and the crude residue was purified via flash 
chromatography (EtOAc/iPrOH/H2O, 27:8:4, v/v) to afford the 
intermediate 9 as a white solid. This material was dissolved in 
autoclaved H2O (20 ml), treated with amano lipase A from 
Aspergillus niger (500 mg, activity 12,000 units/g) and incu-
bated at 37 °C for 48 h. The solution was filtered through an 
Amicon filter and lyophilized to afford the title product as a 
white solid (952 mg, 59%). Spectral properties of the desired 
product matched those described previously (41).
Crystallography
To obtain the complex structure of BtGH84-glycolic acid, 
apo-BtGH84 crystals, grown as described previously (18), were 
soaked in a drop containing 0.1 M NH4OAc, 15% (w/v) 
PEG3350, 20% glycerol, and 0.4 M glycolic acid at pH 6.0 over-
night. The crystals were subsequently flash-frozen in liquid 
nitrogen prior to data collection. X-ray data of BtGH84-glycolic 
acid were collected from a single crystal to 2.0 Å on beamline 
ID14-1 at the European Synchrotron Radiation Facility. All data 
were integrated using MOSFLM (42), followed by data scaling 
and merging with SCALA from the CCP4 suite of program 
CCP4 suite (43). The structure was solved using molecular 
replacement method using the apo structure (Protein Data 
Bank code 2CHO) as an initial searching model. Manual cor-
rections to the model were made with COOT (44), and refine-
ment cycles were performed with REFMAC (45).
The D242N-glycolyl oxazoline complex was obtained by 
soaking of D242N crystals (46) in a drop containing crystalliza-
tion mother liquor supplemented with a minute amount of 
pNP-GlcGc 7 for 5 min. Soaked crystals were then quickly 
transferred to a second drop comprising the same solution 
with glycerol concentration raised to 20% (w/v) before the 
crystals were flash-frozen in liquid nitrogen. Data for 
D242N-glycolyl oxazoline were collected at the European 
Synchrotron Radiation Facility (Grenoble) to 2.25 Å resolu-
tion on beamline ID29. Data processing and structure solu-
tion were performed essentially as described for the
passively diffuse into the cell. With these complications in
mind, the growth rate data for EMEG32/ cells treated with
ManNGc does suggest that it can be epimerized to GlcNGc,
which together with the growth rate rescue observed using
ManNAc suggests that GlcNAc 2-epimerase is operative in
these cells. The data further suggest that the HBSP is likely
capable of converting GlcNGc to UDP-GlcNGc.
Analysis of UDP-GlcNAc Levels—To test if exogenously
added GlcNGc can be converted to UDP-GlcNGc within
EMEG32/ cells, we used a capillary electrophoresis assay to
analyze levels of NDP-sugars from cells. When EMEG32/
cells were incubated with 5mMGlcNAc overnight, the levels of
UDP-GlcNAc dramatically increased as expected (Fig. 3A,
GlcNAc). On incubation with 5 mM GlcNGc, two new peaks
appeared in the electrophoretogram (Fig. 3A, GlcNGc, peaks 2
and 5).One peak corresponds to a species eluting slightly before
UDP-GlcNAc (Fig. 3A, peak 2). We confirmed that this was a
distinct species by mixing samples derived from cells treated
with a mixture of GlcNAc and GlcNGc (Fig. 3A, mixture). A
second new species gave rise to a peak (Fig. 3A, peak 5) eluting
between UDP-Glc and UDP-GalNAc. We hypothesized that
the two new peaks were UDP-GlcNGc and, because UDP-
GalNAc is made directly fromUDP-GlcNAc, UDP-GalNGc. In
the absence of standards, however, the identity of these two
new peaks could not be unambiguously assigned. Accordingly,
synthetic standards of UDP-GlcNGc 12 and UDP-GalNGc 14
were prepared enzymatically from chemically synthesized
GlcNGc-1-P 6 (Scheme 2).We used two recombinant enzymes
for this biosynthesis as follows: Agx1, a UDP-HexNAc pyro-
phosphorylase that catalyzes the transfer of UMP from UTP to
GlcNAc-1-P, and GalE, a UDP-HexNAc 4-epimerase that cat-
alyzes the interconversion of UDP-GlcNAc and UDP-GalNAc.
As shown in Fig. 3B, Agx1 yielded UDP-GlcNAc 11when incu-
bated with GlcNAc-1-P and UTP (Scheme 2). When GalE was
added to the resulting reactionmixture, a second peak could be
observed in the electrophoretogram that corresponded to
UDP-GalNAc 13, which indicates that these enzymes are
active. When GlcNGc-1-P was used as a substrate for Agx1, a
peak was observed that eluted from the capillary slightly before
UDP-GlcNAc, and importantly, this peak has the same electro-
phoretic mobility as the first new peak (peak 2) from the cells
treated with GlcNGc. When GalE was added to this reaction
mixture (Scheme2), another species eluted from the capillary at
the same time as the second new peak (peak 5) observed in the
sample obtained from cells treated with GlcNGc. Carrying out
a reaction with GlcNAc-1-P and GlcNGc-1-P at equimolar
concentrations in the presence of Agx1 andGalE resulted in the
production of the expected four product peaks (Fig. 3B, peaks 2,
3, 5, and 6). It should be noted that the two enzymes we use
here, Agx1 and GalE, are recombinant human enzymes. These
observations therefore support the ability of these enzymes to
process substrates having the glycolyl moiety in human cells
and other eukaryotes, such asmice, in which these enzymes are
highly conserved at the amino acid level. Although a quantita-
tive kinetic analysis was not performed, it should be noted that
in Fig. 3B both UDP-GlcNAc 11 and UDP-GlcNGc 12 were
produced quantitatively. Also, the absolute amount of UDP-
GlcNGc produced in cells treated with 5 mMGlcNGc is similar
FIGURE 2. GlcNGc and ManNGc rescue the growth rate of EMEG32/ 
mouse embryonic fibroblasts. Approximately 5000 EMEG32/ (A and C) 
EMEG32/ (B and D) cells were plated onto 12-well plates and at the end of 5 
days of growth; the cells were counted on a hemocytometer to obtain the 
doubling time. Cells were cultured with the indicated concentration of 
GlcNAc or GlcNGc (A and B) and ManNAc or ManNGc (C and D) through the 
experiment. Each experimental condition was repeated in at least triplicate, 
and the errors represent the standard deviation between these replicates.
the growth rate essentially matched that observed when using 
GlcNAc (Fig. 2A). Above 10 mM GlcNGc, cells began to grow 
more slowly, and this appears to be specific to GlcNGc treat-
ment in EMEG32-deficient cells, because we do not observe the 
same effect when using GlcNGc in EMEG32/ cells (Fig. 2B). 
These results suggested to us that it might be that GlcNGc is 
being converted to UDP-GlcNGc, which can compensate for 
decreased UDP-GlcNAc and thereby rescue growth. Following 
the idea that GlcNGc might be derived from Neu5Gc, we 
treated EMEG32/ cells with various concentrations of 
ManNAc and found that high concentrations of ManNAc also 
rescued their growth rate (Fig. 2C). The high concentration of 
ManNAc required to observe this effect is in keeping with ear-
lier reports showing that ManNAc is not as readily taken up 
into the cell as is GlcNAc (48) and that uptake of ManNAc is 
nonsaturable up to a concentration of 20 mM (49). When using 
ManNGc, we found a minor increase in growth rate at 20 mM; 
however, the difference did not reach statistical significance 
(p  0.09) (Fig. 2C). Furthermore, we found that 20 mM 
ManNGc had a slightly deleterious effect on the growth rate of 
EMEG32/ cells (Fig. 2D). This latter observation suggested 
to us that the effect of ManNGc on the growth rate of 
EMEG32/ cells might be complicated by two countervailing 
effects. The first is that epimerization of ManNGc to GlcNGc 
might result in increased UDP-GlcNGc levels, and this could 
rescue the growth rate by substituting for UDP-GlcNAc. The 
second is that high levels of ManNGc or some metabolic inter-
mediate derived from ManNGc might have a deleterious effect 
on growth rate. An additional complication is that because 
ManNAc appears to only gain access to the cell through passive 
diffusion (49), the additional hydroxyl group of the glycolyl unit 
of ManNGc might compromise the ability of this molecule to
plementary evidence for the metabolic promiscuity of the
HBSP and GalE by showing exogenous GalNGc is converted to
both UDP-GalNGc and UDP-GlcNGc in cultured mammalian
cells.
Immunoblot Evidence for Modification of Proteins with
O-GlcNGc—Having established that UDP-GlcNGc 12 can be
biosynthesized within cells, it follows that it may be used as a
substrate by OGT. OGT has been previously shown to use uri-
dine diphosphateN-azidoacetylglucosamineUDP-GlcNAz as a
substrate (24), which suggests that it might be able to use UDP-
GlcNGc 12 with reasonable efficiency because the azide and
hydroxyl substituents of the compounds are similar in size. To
test this possibility, we treated EMEG32/ cells for 24 hwith 5
mM GlcNAc or GlcNGc, after which O-GlcNAc levels were
analyzed by Western blot using the CTD110.6 anti-O-GlcNAc
antibody (Fig. 4A). As measured this way, we find that
O-GlcNAc levels increased substantially in cells treated with 5
mM GlcNAc compared with control cells, which is in line with
the large increase in UDP-GlcNAc levels observed when these
cells were treated with 5 mM GlcNAc (Fig. 4A). In contrast, the
immunoreactivity of lysates derived from cells treated with 5
mM GlcNGc was greatly diminished compared with control
cells despite equivalent loading of all samples. Initially, this
result was surprising to us and prompted the investigation of
two other anti-O-GlcNAc antibodies (RL2 and HGAC85). We
therefore tested these antibodies and observed a similar phe-
nomenon (Fig. 4, B and C). Interestingly, EMEG32/ cells
treated with 20 mM of either ManNAc or ManNGc showed a
similar trend except that the differences in levels of immunore-
activity were not as dramatic (Fig. 4D). Two possibilities could
account for the observed decreases in immunoreactivity. The
first possibility is that these antibodies have decreased binding
affinity to possible O-GlcNGc-modified proteins. The second
possibility is that some GlcNGc metabolite could act as an
inhibitor of OGT. To test the first possibility, the CTD110.6
anti-O-GlcNAc antibody was analyzed for its ability to bind
GlcNAc andGlcNGcby preincubating it with different concen-
trations of GlcNAc or GlcNGc prior to using it in a Western
blot. We found that at least 100-fold more GlcNGc is required
to block antibody binding (Fig. 4E). Thus, the CTD110.6 anti-
body has a preference for the 2-acetamido group of GlcNAc
over the 2-N-glycolyl group of GlcNGc, and the decrease in
immunoreactivity observed in lysates from EMEG32/ cells
treated with GlcNGc orManNGc could represent the accumu-
lation of -O-linked GlcNGc on nucleocytoplasmic proteins.
Evidence for Modification of Proteins with O-GlcNGc by
HPLC Analysis—To obtain more direct evidence for the pres-
ence of O-GlcNGc-modified proteins, we monitored GlcNAc
or GlcNGc enzymatically liberated from proteins by anion-ex-
change HPLC. GlcNAc or GlcNGc was released from proteins
using a bacterial homolog of OGA from B. thetaiodomicron
(BtGH84). This enzymewas used because of the following: (i) it
can efficiently remove O-GlcNAc frommodified proteins (18);
(ii) it can be expressed recombinantly at high levels, which
allows the use of large quantities to drive reactions toward com-
pletion (18), and (iii) it hydrolyzes GlcNGc glycosides only
slightly less efficiently than GlcNAc (see below). EMEG32/
cells (5  107) were treated with either 5 mM GlcNAc or
FIGURE 3. UDP-GlcNGc and UDP-GalNGc can be biosynthesized from 
exogenously supplied GlcNGc in EMEG32/ mouse embryonic fibro-
blasts. A, EMEG32/ cells were treated for 24 h with either 5 mM GlcNAc or 
GlcNGc. Cells were then harvested, and nucleotide mono-, di-, and triphos-
phate-containing compounds were isolated from cell extracts and analyzed 
by capillary electrophoresis. Commercially available standards (upper trace) 
established the electrophoretic mobilities of the following: 1) GDP-Glc (8.6 
min; used as an internal standard); 3) UDP-GlcNAc 11 (8.9 min); 4) UDP-Glc (9.3 
min); 6) UDP-GalNAc 13 (9.85 min); and 7) UDP-Gal (10.2 min). Peaks labeled 2 
(8.8 min) and 5 (9.75 min) are unique to cells treated with GlcNGc and mixing 
samples from GlcNAc- and GlcNGc-treated cells (mixture) strongly suggest-
ing that peak 2 is not the peak arising from UDP-GlcNAc. B, to establish the 
identity of peaks 2 and 5, GlcNAc-1-P and GlcNGc-1-P were converted to 
UDP-GlcNAc and UDP-GlcNGc, respectively, by the enzyme Agx1. Addition-
ally, UDP-GlcNAc and UDP-GlcNGc 12 were converted to UDP-GalNAc 13 and 
UDP-GalNGc 14, respectively, by the epimerase GalE.
to the amount of UDP-GlcNAc formed when cells were treated
with 5 mM GlcNAc. These data indicate that the enzymatic
machinery of the HBSP in mammals is capable of efficiently
converting GlcNGc to UDP-GlcNGc 12 as well as
UDP-GalNGc 14. An accompanying paper (50) provides com-
The interpretation was initially complicated by the fact that in
all the assays, no peak had the same retention time as the
GlcNGc standard. Therewas, however, a peak in all the samples
treated with GlcNGc that eluted 0.4 min earlier than the
GlcNGc standard does, and significantly, this peak was larger
when analyzing lysates from cells incubated with GlcNGc and
then digested with WT BtGH84 (Fig. 5B). To investigate
whether this peak corresponded to GlcNGc, and whether it
simply eluted earlier because of other factors, such as the com-
position of the sample, we carried out an additional experiment
(Fig. 5C). As mentioned above, analysis of lysates from
GlcNAc-treated cells, which were never exposed to exoge-
nously addedGlcNGc, revealed no peaks having an elution time
corresponding to either the GlcNGc standard or the peak
FIGURE 4. Effect of GlcNGc and ManNGc on O-GlcNAc levels in EMEG32/ mouse embryonic fibroblasts. Cells were treated for 24 h with either 5 mM of
GlcNAc or GlcNGc (A–C) and 20 mM ManNAc or ManNGc (D). O-GlcNAc levels were assessed by Western blot analyses using three different O-GlcNAc antibodies.
In all cases, cells treated with GlcNGc or ManNGc show lower immunoreactivity using these antibodies (A and D, CTD110.6; B, RL2; C, HGAC85). The upper panels
represents Western blots with the specified anti-O-GlcNAc antibody, and the lower panels are Western blots obtained using an anti--actin to demonstrate equal
loading of samples. E, CTD110.6 anti-O-GlcNAc antibody binds GlcNGc with lower affinity than GlcNAc. The antibody was incubated with the specified concentration
of either GlcNAc or GlcNGc for 10 min prior to as well as during probing of the blots containing cell lysates from EMEG32/ cells treated with GlcNAc.
SCHEME 2. (i) UTP, Agx1; (ii) GalE.
GlcNGc for 48 h, and desalted cell lysates were incubated with 
active BtGH84 (WT BtGH84) or inactive mutant BtGH84 
(BtGH84-D242A). Despite two rounds of desalting, we find 
sample lysates from cells treated with GlcNAc contained a 
small amount of GlcNAc even without adding BtGH84 (Fig. 5A, 
Enzyme (t  0)). When the lysates were incubated with the 
inactive mutant BtGH84-D242A, the size of the peak corre-
sponding to GlcNAc remained unchanged (Fig. 5A,  Mut 
Enzyme). However, digestion of lysates with WT BtGH84 
greatly increased the size of the peak corresponding to GlcNAc 
(Fig. 5A,  WT Enzyme). The results obtained for the lysates 
derived from cells treated with GlcNGc appear initially to be 
more challenging to interpret (Fig. 5B); therefore, we carried 
out several additional controls (Fig. 5C) to clarify the results.
GlcNGc and its retention time differs from that of the standard
due to the composition of the samples; the standard is in water,
and the experimental sample contains other small molecules
that can affect electrophoretic mobility.
Dynamic Addition and Removal of GlcNGc—The results of
the HPLC assay shown above indicate that EMEG32/ cells
treated with GlcNGc have terminal -O-linked GlcNGc within
their glycoconjugates. It is possible that some of this GlcNGc is
contained within soluble glycoconjugates other than O-
GlcNGc present on nucleocytoplasmic proteins. Yet, as many
other forms of glycoconjugates are found on proteins stably
associated with membranes and on secreted proteins, many of
these would have been removed by washing the cells and by the
centrifugation step following cell lysis. One hallmark of the
O-GlcNAc modification of nucleocytoplasmic proteins is its
dynamic nature (14). To assess the time-dependent addition
and removal of GlcNGc from proteins in EMEG32/ cells, we
cultured cells for 48 h in the presence of either 5mMGlcNAc or
GlcNGc. After this time, the cells were washed, and the media
were changed to media containing the other compound. Cells
were then harvested at various times after switching the media
to analyze O-GlcNAc levels by Western blot. When cells were
initially grown in GlcNGc and then switched to GlcNAc, we
found a time-dependent increase in O-GlcNAc immunoreac-
tivity up to amaximumat 48 h (Fig. 6A). This increase in immu-
noreactivity represents the removal of GlcNGc from proteins
and subsequent addition of GlcNAc. Based on these data, we
estimate the half-life for this process to be 24 h. Interestingly, to
our knowledge only two published studies have attempted to
quantify the dynamics of O-GlcNAc; one study estimated a
half-life for O-GlcNAc of 48 h on a cytokeratin (51), and
another study estimated a half-life of 12 h on an -crystallin
(17). Although many factors likely contribute to the residency
time ofO-GlcNAc (orO-GlcNGc) on proteins, the global rates
that are estimated from these data are in line with the rates
determined previously on individual proteins. When we first
cultured cells in media containing GlcNAc and then switched
to media containing GlcNGc, O-GlcNAc immunoreactivity
showed a time-dependent decrease over 48 h (Fig. 6B). In this
experiment, the decrease in signal represents the combined
processes of removal of GlcNAc from proteins and subsequent
addition of GlcNGc. These results support the view that the
GlcNGc can be added to and removed from proteins in a
dynamic manner consistent with that observed for O-GlcNAc.
O-GlcNGc inCells Having an IntactHBSP—The evidencewe
present thus far forO-GlcNGcmodification of nucleocytosolic
proteins in cells treated with GlcNGc comes from EMEG32/
cells, which lack a functional HBSP and cannot therefore inde-
pendently biosynthesize GlcNAc. To investigate if exogenously
added GlcNGc is able to compete with the regular flux through
the HBSP in cells containing a functional HBSP, EMEG32/
cells were used because they have normal UDP-GlcNAc levels
(47); consistent with this, their growth rate is not dependent on
exogenously added GlcNAc (Fig. 2B). We speculated that if
GlcNGc can compete withGlcNAc endogenously produced via
the HBSP, then exogenously added GlcNGc should result in
decreased O-GlcNAc immunoreactivity. To test this proposal,
we treated EMEG32/ cells for 48 h with either 5mMGlcNAc
FIGURE 5. Direct support for the attachment of GlcNGc to proteins via a 
-O-linkage. EMEG32/ cells were treated with either 5 mM GlcNAc (A) or 5  
mM GlcNGc (B) for 24 h. Cell lysates were incubated with 1 mg/ml BtGH84 for 
60 min, and protein was removed by ethanol precipitation. The samples were 
then analyzed by anion-exchange HPLC. For cells treated with GlcNAc, sam-
ples were analyzed on a PA20 (strong binding) with a mobile phase consisting 
of 20 mM NaOH and an internal standard of 20 M fucose. For cells treated 
with GlcNGc, samples were analyzed on a PA100 (weaker binding) with a 
mobile phase consisting of 100 mM NaOH and an internal standard of 20 M 
maltose. The internal standards were added into the samples prior to BtGH84 
digestion to assess the percent recovery through handling steps. The reten-
tion times of GlcNAc (7.4 min) and GlcNGc (11.1 min) standards were used to 
determine the peak corresponding to these species from the reactions. C, var-
iation in the retention time of GlcNGc observed when assaying standards 
compared with samples derived from cell lysates was resolved by adding a 
standard to lysates. Samples derived from cells treated with GlcNAc, but with-
out added BtGH84, were assayed both with and without added 1 M GlcNGc.
observed in the digested GlcNGc-treated cell lysates. When a
small amount (2 M) of GlcNGc was added to this cell lysate, a
new peak appeared that eluted 0.4 min earlier than did the
GlcNGc standard, and significantly, this new peak aligned with
the peak hypothesized to be GlcNGc in the lysates obtained
from GlcNGc-treated cells. Accordingly, this peak arises from
glycolyl-containing substrates as compared with the lysosomal
HexB, the structureofwhichreveals there isnopocketbeneath the
2-acetamidogroup (53, 54).Thishighly conservedpocket (Fig. 1,B
and C) found in N-acetylglucosaminidases from GH84 is highly
conserved and is likely present to ensure that anyO-GlcNGc, or
other adventitiously incorporated GlcNAc analogs, formed
within cells can be removed and not accumulate on proteins.
Molecular Basis for the Ability of OGA to Process of GlcNGc
Substrate—In an effort to provide structural insight into
GlcNGc binding toOGA, we solved the structure of BtGH84 in
complex with glycolic acid. BtGH84 is a good model of human
OGA because active site residues are entirely conserved
between these two enzymes. The rationale for using glycolic
acid was that the initial “apo” BtGH84 structure had shown a
molecule of acetate binding in the N-acetyl binding “pocket”
and glycerol (used as a cryo-protectant) binding in place of the
O4-C4-O5-C5-C6-O6 atoms of N-acetylglucosamine; the two
fragments mimicked well the position of the natural substrate
(18). When glycolate was soaked into the apo-crystal, we
observed it bound in a position previously occupied by an ace-
tatemolecule, suggesting this is representative of the binding of
the N-glycolyl moiety of GlcNGc (together also with the bind-
ing of glycerol, Fig. 9, A and B (supplemental Table 1)). Inter-
estingly, the hydroxyl group of glycolic acid displayed different
binding modes in the two molecules found within the unit cell
of the crystal. In molecule A, it forms OH- interactions with
Tyr-282 (3.4 Å from ring center) and makes one H-bond with
the thiol functionality of Cys-278. In molecule B, this hydroxyl
group is within hydrogen bond distance to carboxyl group of
Asp-242 and also makes OH- interactions with Trp-337 (2.6
Å from ring center). The different binding modes observed for
this hydroxyl group implies high mobility of the molecule
within the crystal, which is also reflected by its relatively higher
B-factor values. To obtain more direct structural evidence for a
catalytically relevant GlcNGc species, we aimed to obtain a
BtGH84 boundGlcNGc structure. To achieve this aim, we built
upon our previous observation of a catalytically competent oxa-
zoline intermediate (46), and thus, by using the D242Nmutant
of BtGH84 in combination with the substrate pNP-GlcNGc 7,
we were able to trap a glycolyl-oxazoline reaction intermediate
bound within the active site. Unambiguous electron density
FIGURE 6. Time course for addition of and removal of GlcNGc from EMEG32/ mouse embryonic fibroblasts. Cells were grown for 48 h in the presence
of 5 mM GlcNGc (A) or GlcNAc (B), and then the media were replaced with media containing 5 mM of the other compound. At various times, the cells were
harvested, and O-GlcNAc levels were assessed by Western blot. The upper panels represent Western blots obtained using the CTD110.6 anti-O-GlcNAc
antibody, and the lower panels are Western blots obtained using an anti--actin, which demonstrates equivalent loading of samples.
FIGURE 7. Effect of GlcNGc and ManNGc on O-GlcNAc levels in EMEG32/ 
mouse embryonic fibroblasts. Cells were treated for 48 h with either 5 mM 
GlcNAc or GlcNGc (A) and either 20 mM ManNAc or ManNGc (B). The upper 
panels represent Western blots obtained using the CTD110.6 anti-O-GlcNAc 
antibody, and the lower panels are Western blots obtained using an anti--
actin to demonstrate equivalent loading of samples.
or GlcNGc, and CTD110.6-positive immunoreactivity present 
in lysates was assessed by Western blot (Fig. 7A). Cells treated 
with GlcNAc showed only a slight increase in O-GlcNAc 
immunoreactivity, whereas cells treated with GlcNGc showed a 
decrease that is consistent with the studies presented above and 
can be accounted for by poor recognition of GlcNGc by the 
antibody. Treatment of EMEG32/ cells with either 20 mM 
ManNAc or ManNGc produced a similar outcome (Fig. 7B). 
Collectively, these data indicate that GlcNGc can feed into the 
HBSP via the HSP and be incorporated as O-GlcNGc in the 
presence of an intact HBSP.
Activity of Human OGA toward pNP-GlcNGc 7—Biochemi-
cal studies of human OGA and the structures of OGA 
homologs (18 –23) have revealed the active site contains a 
pocket that might enable processing O-GlcNGc-modified pro-
teins and other GlcNGc glycosides. To address this question, 
we prepared (Scheme 1) pNP-GlcNGc, 7 and tested it as a sub-
strate for both human OGA and HexB. Consistent with the 
cell-based studies, we find that OGA is able to catalyze cleavage 
of this substrate (Fig. 8A) with a catalytic efficiency (Vmax/[E]Km) 
toward pNP-GlcNGc that is 48-fold lower compared with 
pNP-GlcNAc (Fig. 8A and Table 1). However, the drop in catalytic 
efficiency of human HexB toward pNP-GlcNGc as compared with 
pNP-GlcNAc was much greater (550-fold) (Fig. 8B and Table 1). 
Therefore, it appears that the large active site pocket of OGA 
revealed previously (18–20, 52) makes it more tolerant toward
revealed the glycolyl oxazoline derivative (Fig. 9C) bound in a
4C1 chair conformation that is essentially identical to that of
previously described D242N-oxazoline (C root mean square
deviation  0.23 Å), with almost invariant active site interac-
tions (Fig. 9D). In brief, the C6 hydroxyl (carbohydrate num-
bering) donates one H-bond to Asp-344. The C4 hydroxyl is
H-bonded to Asp-344 and Asn-372. The C3 hydroxyl
receives one H-bond from the main chain carbonyl of Gly-
135. The oxazoline ring nitrogen is H-bonded to Asp-242,
although the oxazoline oxygen receives one H-bond from
Asn-339. One notable feature of the new structure lies in the
glycolyl hydroxyl group, which is closely sandwiched by Trp-
337 and Tyr-282, to form an H-bond with the thiol of Cys-
278 at the bottom of the active site. These two structures
therefore support the hypothesis that BtGH84 is able to bind
and process metabolically derivedO-GlcNGc and also offer a
structural rationale for this binding.
Conclusions—These collective observations support the view
conservation among mammals, it appears likely that GlcNGc
could be found in a wide range of tissues andmammals.
The consequence of these observations and the biological
significance of O-GlcNGc and how it might interact with
O-GlcNAc are difficult to predict. Clearly, GlcNGc can substi-
tute for GlcNAc as measured by its ability to rescue the growth
rate of EMEG32/ cells (Fig. 2A). One interesting possible
scenario is that cells under certain metabolic pressures might
produce various short chain fatty acids that could be incorpo-
rated to form analogs of GlcNAc, and this may either confer
some adaptive benefit or bemaladaptive. It is interesting in this
regard that short chainN-acyl variants have been found on the
lysine residues of histones (55). These alternativemodifications
are likely derived from cellular pools of propionyl-CoA and
butyryl-CoA as acetyltransferases can use these substrates with
reasonable efficiency (for review seeRefs. 56, 57).Whether such
variants have biologically significant roles, or are the conse-
quence of the imperfection of enzymatic processes in their abil-
ity to distinguish small structural variants of substrates,
remains a topic of interest. In this regard, it should be noted that
although we find good support for O-GlcNGc being able to
occur, there is no evidence to support that it is an abundant or
functionally distinct species. In this regard, however, the
accompanying paper (26) provides clear evidence for GlcNGc
and GlcNGc 6-phosphate as true catabolic intermediates
derived from Neu5Gc, which is abundant in nonhuman verte-
brates. Indeed, even if GlcNGc levels are significantly lower
than GlcNAc levels and the efficiency of processing of GlcNGc
is lower than that of GlcNAc, principles of enzyme kinetics
dictate that inevitablyO-GlcNGcwill form at some level. Given
that we show here that UDP-GlcNGc and UDP-GalNGc are
formed within cells from GlcNGc, it seems very possible that
other glycan structures could incorporate N-glycolyl-hexo-
samines. Consistent with this view, in an accompanying paper
FIGURE 8. Activity of human OGA and HexB toward pNP-GlcNGc (7). The catalytic efficiency of human OGA (A) and HexB (B) was assessed by obtaining full
Michaelis-Menten plots against pNP-GlcNAc (squares) and pNP-GlcNGc (circles). Insets show that rates with the glycolyl derivative were slower but did show
Michaelis-Menten behavior.
TABLE 1
Enzymatic parameters describing the hydrolysis of pNP-GlcNAc and pNP-GlcNGc 7 by human OGA and HexB
Enzyme Substrate Vmax/[E]0 Km Vmax/[E]0Km (Vmax/[E]0 Km)Ac/(Vmax/[E]0Km)Gc
mol min1 mg1 mM mol min1 mg1mM1
OGA pNP-GlcNAc 1.8 0.55 3.3 48
pNP-GlcNGc 0.15 2.2 0.068
HexB pNP-GlcNAc 25 0.71 36 550
pNP-GlcNGc 0.32 4.9 0.065
that O-GlcNGc modification of nucleocytoplasmic proteins 
can occur from metabolites such as GlcNGc and GlcNGc 
6-phosphate that are generated by catabolism of Neu5Gc as 
shown in an accompanying paper (26). Less likely, based on data 
from another accompanying paper (50) is that GlcNGc could 
arise by de novo synthesis of GlcNGc via the HBSP. We also find 
that GlcNGc introduced to cells having a functional HBSP can 
compete with the normal flux through the HBSP and become 
covalently attached to nucleocytosolic proteins as O-GlcNGc. 
Interestingly, O-GlcNGc can turn over within a similar time 
frame as O-GlcNAc, indicating that the enzymes involved have 
a fair level of tolerance for this monosaccharide and for O-
GlcNGc. Enzyme kinetic and structural studies reveal the quan-
titative and structural basis for the tolerance of OGA toward O-
GlcNGc, supporting the cell-based observations. Given the ubiq-
uitous nature of the HBSP, OGA, and OGT in tissues and their
possibility is a topic of interest given the observations regarding
metabolic promiscuity of glycosylation pathways and glycosyl-
transferases made in this and the accompanying papers (26,
50).
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FIGURE 9. Three-dimensional structures of glycolic acid and glycolyl oxazoline bound within the N-acyl binding pocket of BtGH84 support the
catalytic competence of OGA toward O-GlcNGc. A and B, binding modes of glycerol and glycolic acid (cyan) to two BtGH84 molecules in the crystal structure
to mimic interactions with the substrate. Electron densities are maximum likelihood weighted 2Fobs  Fcalc countered at 1	. Hydrogen bonds, within 3.2 Å, to
enzyme active site residues are shown as dashed lines. C, the glycolyl-oxazoline intermediate (magneta) bound to the D242N variant of BtGH84. D, overlay of
D242N-glycolyl oxazoline with D242N-oxazoline (green), highlighting invariant interactions in both structures. These figures were drawn with PyMOL.
(50), we show that GalNGc can be incorporated into various cell 
surface glycans. Notably, even enzymatic activities that are both 
ancient and critical for life, including DNA and protein biosyn-
thesis, show less than complete fidelity. In response to such 
enzymatic promiscuity, adaptive mechanisms have evolved to 
correct and cope with such errors (5–7). Here, we propose that 
the active site pocket of OGA and the substrate promiscuity of 
OGA are highly conserved exactly because of the lack of complete 
fidelity of the HBSP and OGT. OGA therefore acts to “proofread” 
the incorporation of variants of GlcNAc. More generally, these 
observations set precedent for the possibility that other carbohy-
drate-processing enzymes may show similar plasticity. This
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